Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 9098 results

  1. Neurostimulation of lumbar multifidus for refractory chronic low back pain with lumbar multifidus dysfunction

    In development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    In development

  2. Topical tapinarof for treating mild to severe plaque psoriasis ID6712: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  3. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  4. Topical tapinarof for treating mild to severe plaque psoriasis ID6712

    In development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    In development Reference number: GID-HTG10172 Expected publication date: TBC

    HealthTech guidance
    In development

  7. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation

  8. Renal sympathetic denervation for resistant hypertension: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 29 June 2026.

    In consultation

  9. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  10. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  11. Urinary biomarker tests to detect bladder cancer

    Awaiting development Reference number: GID-HTG10903 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628

    In development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 July 2026.

    Technology appraisal guidance
    In consultation